{"id":"vaccine-administration","rwe":[],"_fda":{"id":"cbdfdf49-509d-47b9-bf3b-2f3fb438768d","set_id":"b99f6b65-fe22-4dc2-97f8-8ab315396f75","openfda":{"upc":["0877730002969"],"unii":["WQZ3G9PF0H","C62OO7VD9K","XK4IUX8MNB","C88X29Y479","324Y4038G2","2E32821G6I","29SUH5R3HU","877L01IZ0P","ETJ7Z6XBU4","2H1576D5WG","0YPR65R21J","70FD1KFU70","1NT28V9397"],"route":["ORAL"],"spl_id":["cbdfdf49-509d-47b9-bf3b-2f3fb438768d"],"brand_name":["Vaccine Support CP"],"spl_set_id":["b99f6b65-fe22-4dc2-97f8-8ab315396f75"],"package_ndc":["43406-0133-1"],"product_ndc":["43406-0133"],"generic_name":["BELLADONNA, CALCAREA CARBONICA, CARCINOSINUM, HYPERICUM PERFORATUM, LEDUM PALUSTRE, LYCOPODIUM CLAVATUM, MALANDRINUM, MERCURIUS SOLUBILIS, NATRUM SULPHURICUM, PYROGENIUM, SARSAPARILLA, SILICEA, SULPHUR, THUJA OCCIDENTALIS"],"product_type":["HUMAN OTC DRUG"],"substance_name":["ATROPA BELLADONNA","HUMAN BREAST TUMOR CELL","HYPERICUM PERFORATUM WHOLE","LYCOPODIUM CLAVATUM SPORE","MERCURIUS SOLUBILIS","OYSTER SHELL CALCIUM CARBONATE, CRUDE","RANCID BEEF","RHODODENDRON TOMENTOSUM LEAFY TWIG","SILICON DIOXIDE","SMILAX ORNATA ROOT","SODIUM SULFATE","SULFUR","THUJA OCCIDENTALIS LEAFY TWIG"],"manufacturer_name":["Natural Creations, Inc"],"is_original_packager":[true]},"purpose":["USES: Temporarily relieves symptoms of runny nose, fever & cough.**"],"version":"2","warnings":["WARNINGS: IF PREGNANT OR BREAST-FEEDING , ask a health care professional before use. KEEP OUT OF THE REACH OF CHILDREN. In case of overdose (or accidental ingestion) get medical help or contact a Poison Control Center right away. Do not use if TAMPER EVIDENT seal is broken or missing."],"questions":["QUESTIONS & COMMENTS? Natural Creations, Inc. / Woodbine, IA 51579 / 712-647-1600"],"references":["**Claims based on traditional homeopathic practice, not accepted medical evidence. Not FDA evaluated."],"effective_time":"20251218","active_ingredient":["ACTIVE INGREDIENTS - equal amounts of: Belladonna 30C, Calcarea Carbonica 30C, Carcinosinum 30C, Hypericum Perforatum 30C, Ledum Palustre 30C, Lycopodium Clavatum 30C, Malandrinum 30C, Mercurius Solubilis 30C, Natrum Sulphuricum 30C, Pyrogenium 30C, Sarsaparilla 30C, Silicea 30C, Sulphur 30C, Thuja Occidentalis 30C"],"inactive_ingredient":["INACTIVE INGREDIENTS: Citric Acid, Glycerin USP, Natural Cherry Flavor, Potassium Sorbate, Purified Water."],"indications_and_usage":["USES: Temporarily relieves symptoms of runny nose, fever & cough.**"],"dosage_and_administration":["DIRECTIONS: Adults & children above 12 years: 10 drops orally 3 times daily, or as directed by a health care professional."],"spl_product_data_elements":["Vaccine Support CP Belladonna, Calcarea Carbonica, Carcinosinum, Hypericum Perforatum, Ledum Palustre, Lycopodium Clavatum, Malandrinum, Mercurius Solubilis, Natrum Sulphuricum, Pyrogenium, Sarsaparilla, Silicea, Sulphur, Thuja Occidentalis ATROPA BELLADONNA ATROPA BELLADONNA OYSTER SHELL CALCIUM CARBONATE, CRUDE OYSTER SHELL CALCIUM CARBONATE, CRUDE HUMAN BREAST TUMOR CELL HUMAN BREAST TUMOR CELL HYPERICUM PERFORATUM WHOLE HYPERICUM PERFORATUM RHODODENDRON TOMENTOSUM LEAFY TWIG LEDUM PALUSTRE TWIG LYCOPODIUM CLAVATUM SPORE LYCOPODIUM CLAVATUM SPORE MERCURIUS SOLUBILIS MERCURIUS SOLUBILIS SODIUM SULFATE SODIUM SULFATE ANHYDROUS RANCID BEEF RANCID BEEF SMILAX ORNATA ROOT SARSAPARILLA SILICON DIOXIDE SILICON DIOXIDE SULFUR SULFUR THUJA OCCIDENTALIS LEAFY TWIG THUJA OCCIDENTALIS LEAFY TWIG CITRIC ACID MONOHYDRATE GLYCERIN POTASSIUM SORBATE WATER"],"keep_out_of_reach_of_children":["KEEP OUT OF THE REACH OF CHILDREN . In case of overdose (or accidental ingestion) get medical help or contact a Poison Control Center right away."],"package_label_principal_display_panel":["NDC:43406-0133-1 Vaccine Support CP HOMEOPATHIC 1 fl oz (30mL) / Alcohol Free Natural Cherry Flavor image description"]},"tags":[],"safety":{"boxedWarnings":[],"drugInteractions":[{"drug":"Warfarin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Aspirin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Ibuprofen","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Acetaminophen","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Corticosteroids","action":"Avoid","effect":"Decreased immune response to vaccine"},{"drug":"Immunosuppressants","action":"Avoid","effect":"Decreased immune response to vaccine"},{"drug":"Live attenuated vaccines","action":"Avoid","effect":"Risk of transmission of vaccine virus"},{"drug":"Interferons","action":"Avoid","effect":"Decreased immune response to vaccine"},{"drug":"Thalidomide","action":"Avoid","effect":"Decreased immune response to vaccine"},{"drug":"Azathioprine","action":"Avoid","effect":"Decreased immune response to vaccine"}],"commonSideEffects":[],"contraindications":["Severe immunodeficiency (e.g., hematologic and solid tumors, receipt of chemotherapy, congenital immunodeficiency, long-term immunosuppressive therapy or patients with HIV infection who are severely immunocompromised)","Pregnancy","Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a vaccine component","Encephalopathy (e.g., coma, decreased level of consciousness, prolonged seizures), not attributable to another identifiable cause, within 7 days after administration of a previous dose of pertussis-containing vaccine","Severe Combined Immunodeficiency (SCID) disease","History of intussusception","Guillain-Barré Syndrome (GBS) <6 weeks after previous dose of tetanus-toxoid–containing vaccine","History of Arthus-type hypersensitivity reactions after a previous dose of diphtheria-toxoid—containing vaccine"],"specialPopulations":{"Pregnancy":"Pregnancy testing not needed before vaccination; HPV vaccination not recommended until after pregnancy; no intervention needed if vaccinated while pregnant. There is currently no ACIP recommendation for Jynneos use in pregnancy due to lack of safety data in pregnant women. Pregnant women with any risk factor described above may receive Jynneos. No recommendation for PCV or PPSV23 due to limited data. Summary of existing data on pneumococcal vaccination during pregnancy can be found at www.cdc.gov/mmwr/volumes/72/rr/rr7203a1.htm","Geriatric use":"text","Paediatric use":"Birth dose (monovalent HepB vaccine only): administer HepB vaccine and hepatitis B immune globulin (HBIG) (in separate limbs) within 12 hours of birth, regardless of birth weight. - Birth weight <2000 grams: administer 3 additional doses of HepB vaccine beginning at age 1 month (total of 4 doses). Adolescents age 18 years may receive: - Heplisav-B: 2-dose series at least 4 weeks apart - PreHevbrio*: 3-dose series at 0, 1, and 6 months - HepA-HepB (Twinrix): 3-dose series (0, 1, and 6 months) or 4-dose series (3 doses at 0, 7, and 21–30 days, followed by a booster dose at 12 months). *Note: PreHevbrio is not recommended in pregnancy due to lack of safety data in pregnant women. History of sexual abuse or assault: Start at age 9 years.  - History of sexual abuse or assault: Start at age 9 years.  - Healthy children ages 2–4 years with any incomplete* PCV series: 1 dose PCV","Renal impairment":"text","Hepatic impairment":"text"}},"trials":[],"aliases":[],"company":"Women and Infants Hospital of Rhode Island","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=Vaccine administration","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-19T23:31:06.492904+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-19T23:31:11.862013+00:00"},"regulatory.eu":{"url":"","method":"api_direct","source":"European Medicines Agency","rawText":"","confidence":1,"sourceType":"ema_api","retrievedAt":"2026-04-19T23:31:06.559605+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Vaccine administration","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-19T23:31:12.331852+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-19T23:31:05.246749+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-19T23:31:05.246772+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL2108573/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:31:13.055048+00:00"}},"allNames":"vaccine support cp","offLabel":[],"timeline":[],"aiSummary":"The drug, a vaccine, is marketed by Women and Infants Hospital of Rhode Island. It is used to prevent COVID-19, Influenza, Human Papillomavirus, Hepatitis A, and Hepatitis B. The vaccine has undergone 100 trials and has been the subject of 3173 publications. It has generated $21.2B in revenue. The mechanism of action is not specified on Wikipedia. The drug's key indications and clinical differentiation are its ability to prevent multiple diseases. Its commercial significance is its high revenue and widespread use. There are no pipeline developments mentioned.","brandName":"Vaccine Support Cp","ecosystem":[],"isGeneric":true,"mechanism":{"target":"unknown","novelty":"best-in-class","modality":"vaccine","drugClass":"vaccine","explanation":"","oneSentence":"","technicalDetail":"The exact mechanism of action for this vaccine is not publicly available. It is likely that the vaccine works by stimulating the body's immune system to produce antibodies against specific pathogens. However, without further information, it is impossible to provide a detailed explanation."},"_companyIR":{"url":"https://www.women.com/investors","revenueRefs":[],"pipelineRefs":[]},"commercial":{"annualCostUS":"$80,000/yr","genericStatus":"Generic — off-patent","currentRevenue":"$21.2B","peakSalesEstimate":"$21.2B"},"references":[{"id":1,"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Vaccine administration","fields":["mechanism","safety","indications","administration"],"source":"FDA Drug Label (DailyMed)"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=Vaccine%20administration","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Vaccine administration","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://www.ebi.ac.uk/chembl/","fields":["molecular"],"source":"ChEMBL (EMBL-EBI)"},{"id":5,"url":"https://www.ema.europa.eu/","fields":["regulatoryStatus"],"source":"European Medicines Agency (EMA)"},{"id":6,"url":"https://list.essentialmeds.org/","fields":["regulatoryStatus"],"source":"WHO Essential Medicines List"}],"_tgaChecked":true,"_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-19T23:31:15.309060+00:00","fieldsConflicting":2,"overallConfidence":0.8},"_whoChecked":true,"biosimilars":[],"competitors":[{"name":"Eiden 2024","company":"FluGen","advantage":"Intranasal delivery of FluGen M2SR influenza vaccine"},{"name":"Eiden 2023","company":"FluGen","advantage":"Intranasal delivery of FluGen M2SR influenza vaccine"},{"name":"Eiden 2022","company":"FluGen","advantage":"Intranasal delivery of FluGen M2SR influenza vaccine"},{"name":"Eiden 2021","company":"FluGen","advantage":"Intranasal delivery of FluGen M2SR influenza vaccine"},{"name":"Fluzone IIV","company":"Unknown","advantage":"Intramuscular seasonal influenza vaccine"},{"name":"LAIV FluMist","company":"Unknown","advantage":"Intranasal seasonal influenza vaccine"},{"name":"BPL-1357","company":"NIH","advantage":"Beta-propiolactone-inactivated quadruple influenza virus cocktail vaccine"},{"name":"rNA","company":"Unknown","advantage":"Intranasal administration of RNA"},{"name":"VXA-A1.1","company":"Vaxart","advantage":"Human-Ad5-based oral influenza vaccine candidate"},{"name":"AuNP-M2e+sCpG","company":"Unknown","advantage":"Gold nanoparticle-conjugated M2e vaccine with a soluble CpG adjuvant"},{"name":"Vaxart VXA-A1.1","company":"Vaxart","advantage":"Human-Ad5-based oral influenza vaccine candidate"}],"genericName":"vaccine administration","indications":{"approved":[{"name":"COVID-19","regulator":"FDA"},{"name":"Influenza","regulator":"FDA"},{"name":"Human Papillomavirus","regulator":"FDA"},{"name":"Hepatitis A","regulator":"FDA"},{"name":"Hepatitis B","regulator":"FDA"},{"name":"Meningococcal","regulator":"FDA"},{"name":"Pneumococcal","regulator":"FDA"},{"name":"Rotavirus","regulator":"FDA"},{"name":"Varicella","regulator":"FDA"},{"name":"Measles, Mumps, and Rubella","regulator":"FDA"}],"offLabel":[],"pipeline":[]},"_mhraChecked":true,"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT02772003","phase":"PHASE1","title":"DNA Vaccine Therapy in Treating Patients With Chronic Hepatitis C Virus Infection","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2016-06-06","conditions":"Chronic Hepatitis, Hepatitis C Infection, Hepatocellular Carcinoma","enrollment":33},{"nctId":"NCT05652504","phase":"PHASE1","title":"Safety Evaluation of PfSPZ Vaccine in Pregnant Women in Mali (MalVIP1)","status":"SUSPENDED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2026-04-01","conditions":"Malaria","enrollment":400},{"nctId":"NCT03387553","phase":"EARLY_PHASE1","title":"HER2 Directed Dendritic Cell Vaccine During Neoadjuvant Therapy of HER2+Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2018-06-06","conditions":"Breast Cancer, Breast Cancer Female, Breast Cancer, Male","enrollment":31},{"nctId":"NCT06162494","phase":"PHASE4","title":"Recombinant Zoster Vaccine in Young Adult Solid Organ Transplant Recipients","status":"ENROLLING_BY_INVITATION","sponsor":"Ann & Robert H Lurie Children's Hospital of Chicago","startDate":"2024-03-18","conditions":"Varicella Zoster","enrollment":80},{"nctId":"NCT07020533","phase":"PHASE1","title":"A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2026-05-08","conditions":"Accelerated Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia","enrollment":46},{"nctId":"NCT05642195","phase":"PHASE1, PHASE2","title":"Evaluation of a Cancer Lysate Vaccine and Montanide (Registered Trademark) ISA-51 VG With or Without the IL-15 Super-Agonist N-803 as Adjuvant Therapy for PD-L1 Negative Non-Small Cell Lung Cancer","status":"SUSPENDED","sponsor":"National Cancer Institute (NCI)","startDate":"2026-04-01","conditions":"Non-Small Cell Lung Cancer, Non-Small Cell Lung Carcinoma, Carcinoma, Non-Small-Cell Lung","enrollment":30},{"nctId":"NCT07169617","phase":"PHASE2","title":"Testing the SurVaxM Vaccine for Lung Cancer Prevention","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-02-25","conditions":"Lung Carcinoma","enrollment":80},{"nctId":"NCT07495124","phase":"PHASE2","title":"IGFBP-2 Vaccine to Prevent Ovarian Cancer Progression in Patients With Serologic Detection of Recurrence","status":"NOT_YET_RECRUITING","sponsor":"University of Washington","startDate":"2026-04-01","conditions":"Fallopian Tube Carcinoma, Ovarian Carcinoma, Primary Peritoneal Carcinoma","enrollment":26},{"nctId":"NCT05703607","phase":"PHASE1, PHASE2","title":"A Study to Learn About a Modified RNA Vaccine Against Shingles in Healthy Adults","status":"TERMINATED","sponsor":"Pfizer","startDate":"2023-01-25","conditions":"Shingles, Herpes Zoster Infection, Human","enrollment":485},{"nctId":"NCT07183709","phase":"PHASE1","title":"Safety and Immunogenicity Trial of PepGNP-COVID19 Vaccine in Adults","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2026-02-02","conditions":"COVID-19","enrollment":60},{"nctId":"NCT05419011","phase":"PHASE2","title":"Testing a Combination of Vaccines for Cancer Prevention in Lynch Syndrome","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-05-08","conditions":"Colorectal Carcinoma, Colorectal Neoplasm, Lynch Syndrome","enrollment":186},{"nctId":"NCT05985681","phase":"PHASE1","title":"Testing RG1-VLP Vaccine to Prevent HPV-related Cancers","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-02-27","conditions":"Human Papillomavirus-Related Carcinoma","enrollment":18},{"nctId":"NCT05212610","phase":"PHASE4","title":"Assessing Safety of Coronavirus Infection (COVID-19) Messenger RNA (mRNA) Vaccine Administration in the Setting of a Previous Adverse Reaction","status":"COMPLETED","sponsor":"University of Michigan","startDate":"2022-03-21","conditions":"COVID-19, Corona Virus Infection","enrollment":137},{"nctId":"NCT05237947","phase":"PHASE4","title":"Single-Dose HPV Vaccination for the Prevention of Cervical Cancer in Young Adult Women in Costa Rica, The PRISMA ESCUDDO Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-03-01","conditions":"Human Papillomavirus-Related Cervical Carcinoma","enrollment":5000},{"nctId":"NCT03017820","phase":"PHASE1","title":"A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2017-04-04","conditions":"B-Cell Non-Hodgkin Lymphoma, Histiocytic and Dendritic Cell Neoplasm, Myelodysplastic Syndrome","enrollment":127},{"nctId":"NCT00001539","phase":"","title":"A Comprehensive Clinical, Microbiological and Immunological Assessment of Patients With Suspected Post Treatment Lyme Disease Syndrome and Selected Control Populations","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"1996-06-13","conditions":"Lyme Disease","enrollment":700},{"nctId":"NCT07464314","phase":"PHASE1","title":"A Study on the Safety and Immune Response of Investigational mRNA Seasonal Flu/COVID-19 Combination Vaccine in Adults","status":"RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2026-03-09","conditions":"Influenza, Human+COVID-19","enrollment":225},{"nctId":"NCT04930783","phase":"PHASE1","title":"NeoVax + CDX-301 and Nivolumab or Pembrolizumab in Melanoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2022-01-03","conditions":"Melanoma, Metastatic Melanoma","enrollment":10},{"nctId":"NCT03361852","phase":"PHASE1","title":"Personalized Neoantigen Cancer Vaccine + Pembrolizumab After Rituximab for Follicular Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2022-03-14","conditions":"Follicular Lymphoma","enrollment":20},{"nctId":"NCT04367883","phase":"","title":"Influenza Vaccination, ACEI and ARB in the Evolution of SARS-CoV2 Infection","status":"RECRUITING","sponsor":"Consorci Sanitari de Terrassa","startDate":"2020-03-01","conditions":"COVID19, Influenza Vaccination, ACE Inhibitors","enrollment":3000},{"nctId":"NCT05108870","phase":"PHASE1, PHASE2","title":"TheraT® Vectors (Vaccines) Combined With Chemotherapy to Treat HPV16 Head and Neck Cancers","status":"NOT_YET_RECRUITING","sponsor":"University of Chicago","startDate":"2026-07-17","conditions":"Human Papilloma Virus, HPV, HPV Positive Oropharyngeal Squamous Cell Carcinoma","enrollment":98},{"nctId":"NCT07492706","phase":"PHASE1","title":"Safety, Tolerability and Immunogenicity of a Maternal Respiratory Syncytial Virus (RSV) Vaccine (MKK900) in Healthy Adult Women","status":"NOT_YET_RECRUITING","sponsor":"MAXVAX Biotechnology Limited Liability Company","startDate":"2026-04-01","conditions":"Respiratory Syncytial Virus (RSV)","enrollment":120},{"nctId":"NCT06805305","phase":"PHASE2","title":"DOC1021 Dendritic Cell Immunotherapy for Treatment of Newly Diagnosed Adult Glioblastoma (GBM)","status":"RECRUITING","sponsor":"Diakonos Oncology Corporation","startDate":"2025-03-17","conditions":"Glioblastoma (GBM)","enrollment":180},{"nctId":"NCT03568058","phase":"PHASE1","title":"Personalized Immunotherapy in Adults With Advanced Cancers Immunotherapy in Adults With Advanced Cancers","status":"COMPLETED","sponsor":"Aaron Miller","startDate":"2018-07-26","conditions":"Advanced Cancer","enrollment":25},{"nctId":"NCT05385042","phase":"NA","title":"Iron and Immune Response to Vaccine (IRONMUM)","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2022-06-18","conditions":"Pregnancy Related","enrollment":171},{"nctId":"NCT06210854","phase":"PHASE2","title":"Assessing Administration of pBI-11 Via Electroporation for the Treatment of Patients With HPV16/18+","status":"NOT_YET_RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2026-05-01","conditions":"HPV Infection","enrollment":48},{"nctId":"NCT06692959","phase":"PHASE2","title":"A Phase II Trial of Neoadjuvant PD-1 Vaccine PD1-Vaxx in Operable MSI High Colorectal Cancer","status":"RECRUITING","sponsor":"University of Southampton","startDate":"2025-06-16","conditions":"Colorectal Cancer","enrollment":44},{"nctId":"NCT00338377","phase":"PHASE2","title":"Lymphodepletion Plus Adoptive Cell Transfer With or Without Dendritic Cell Immunization in Patients With Metastatic Melanoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2006-02-01","conditions":"Melanoma","enrollment":1230},{"nctId":"NCT06738355","phase":"NA","title":"PREVENT Pilot HPV - Related Cancers Trial","status":"COMPLETED","sponsor":"University of Utah","startDate":"2025-05-20","conditions":"HPV Vaccination, Uptake Vaccination, Series Completion","enrollment":335},{"nctId":"NCT07300267","phase":"PHASE1","title":"A Clinical Study of Novel Pneumococcal Vaccine V118C in Children (V118C-002)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2026-01-13","conditions":"Pneumococcal Infection","enrollment":210},{"nctId":"NCT05037279","phase":"PHASE3","title":"Evaluating Safety and Efficacy of Verity-BCG in BCG-naïve Patients With Intermediate and High-risk Non-muscle Invasive Bladder (NMIBC)","status":"RECRUITING","sponsor":"Verity Pharmaceuticals Inc.","startDate":"2024-04-24","conditions":"Bladder Cancer, Bladder Cancer Recurrent, Neoplasm Recurrence","enrollment":540},{"nctId":"NCT06489964","phase":"NA","title":"Addressing Unfunded Vaccines Through a Co-payment Mechanism in Pharmacies","status":"RECRUITING","sponsor":"Canadian Immunization Research Network","startDate":"2025-10-23","conditions":"Preventable Disease, Vaccine","enrollment":600},{"nctId":"NCT06658405","phase":"PHASE2","title":"Clinical Trial Evaluating Secondary HPV Vaccination After Treatment of High-grade Cervical Lesions","status":"RECRUITING","sponsor":"Centre Oscar Lambret","startDate":"2025-01-13","conditions":"Cervical Lesion","enrollment":85},{"nctId":"NCT07083479","phase":"","title":"Expanded Access Protocol of ELI-002-102 in Subjects With KRAS/NRAS Mutated Pancreatic Ductal Adenocarcinoma","status":"AVAILABLE","sponsor":"Elicio Therapeutics","startDate":"","conditions":"Pancreatic Ductal Adenocarcinoma, KRAS G12D, KRAS G12V","enrollment":""},{"nctId":"NCT05726864","phase":"PHASE1, PHASE2","title":"A Study of ELI-002 7P in Subjects With KRAS/NRAS Mutated Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Elicio Therapeutics","startDate":"2023-04-14","conditions":"Pancreatic Ductal Adenocarcinoma, Colorectal Cancer, KRAS G12D","enrollment":158},{"nctId":"NCT04298606","phase":"EARLY_PHASE1","title":"A Vaccine (CIMAvax-EGF) for the Prevention of Lung Cancer Development or Recurrence","status":"COMPLETED","sponsor":"Roswell Park Cancer Institute","startDate":"2021-11-22","conditions":"Chronic Obstructive Pulmonary Disease, Lung Non-Small Cell Carcinoma, Pneumonia","enrollment":20},{"nctId":"NCT04943848","phase":"PHASE1","title":"rHSC-DIPGVax Plus Checkpoint Blockade for the Treatment of Newly Diagnosed DIPG and DMG","status":"RECRUITING","sponsor":"Ann & Robert H Lurie Children's Hospital of Chicago","startDate":"2022-01-10","conditions":"Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, H3 K27M-Mutant","enrollment":36},{"nctId":"NCT05846516","phase":"PHASE1","title":"A Study to Test KISIMA-02 Vaccine-based Immunotherapy and Ezabenlimab in People With Pancreatic Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Boehringer Ingelheim","startDate":"2023-05-11","conditions":"Pancreatic Ductal Adenocarcinoma","enrollment":58},{"nctId":"NCT06927297","phase":"PHASE1","title":"Phase I Study of the Safety, Tolerability, and Efficacy of an Engineered Mitochondrial Vaccine in Advanced Solid Tumors","status":"RECRUITING","sponsor":"West China Hospital","startDate":"2025-05-09","conditions":"Advanced Solid Tumor Malignancies, Advanced Solid Malignancies","enrollment":12},{"nctId":"NCT07473986","phase":"","title":"REAl LIfe\" Observational Study on the Effectiveness of Evusheld Prophylaxis Against SARS-CoV-2 Omicron Variants in Vaccine Non-responder Immunocompromised Patients","status":"COMPLETED","sponsor":"Fondazione IRCCS Policlinico San Matteo di Pavia","startDate":"2022-07-08","conditions":"SARS-CoV-2 Omicron Variants","enrollment":88},{"nctId":"NCT04936529","phase":"PHASE2","title":"A Study of a Vaccine in Combination With β-glucan and GM-CSF in People With Neuroblastoma","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2021-08-02","conditions":"Neuroblastoma","enrollment":286},{"nctId":"NCT02648282","phase":"PHASE2","title":"Study With CY, Pembrolizumab, GVAX Pancreas Vaccine, and SBRT in Patients With Locally Advanced Pancreatic Cancer","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2016-07-18","conditions":"Pancreatic Cancer","enrollment":58},{"nctId":"NCT02886065","phase":"PHASE1","title":"A Study of PVX-410, a Cancer Vaccine, and Citarinostat +/- Lenalidomide for Smoldering MM","status":"ACTIVE_NOT_RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2017-03-07","conditions":"Smoldering Multiple Myeloma","enrollment":19},{"nctId":"NCT06926062","phase":"NA","title":"Interpersonal Communication Training and Vaccination Workflow Training Alone and in Combination to Improve Communication and Recommendations About HPV Vaccination in Pharmacies, IMPACT HPV Trial","status":"NOT_YET_RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2026-06-01","conditions":"Human Papillomavirus-Related Carcinoma","enrollment":1900},{"nctId":"NCT05843448","phase":"PHASE1","title":"IDO and PD-L1 Peptide Based Immune-Modulatory Therapeutic (IO102-IO103) in Combination With Pembrolizumab for BCG-Unresponsive or Intolerant, Non-Muscle Invasive Bladder Cancer","status":"RECRUITING","sponsor":"University of California, Davis","startDate":"2023-04-19","conditions":"High Risk Non-Muscle Invasive Bladder Urothelial Carcinoma, Stage 0a Bladder Cancer AJCC v8, Stage 0is Bladder Cancer AJCC v8","enrollment":30},{"nctId":"NCT02316457","phase":"PHASE1","title":"RNA-Immunotherapy of IVAC_W_bre1_uID and IVAC_M_uID","status":"COMPLETED","sponsor":"BioNTech SE","startDate":"2016-10","conditions":"Breast Cancer (Triple Negative Breast Cancer (TNBC))","enrollment":42},{"nctId":"NCT05876377","phase":"","title":"Use and Effectiveness of COVID-19 Vaccines Using State Vaccine Registries and Insurance Claims Data","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2023-10-23","conditions":"SARS-CoV-2, COVID-19, Post-Acute COVID-19 Syndrome","enrollment":1},{"nctId":"NCT02287428","phase":"PHASE1","title":"Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With Newly Diagnosed GBM","status":"RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2014-11","conditions":"Glioblastoma","enrollment":56},{"nctId":"NCT07097012","phase":"PHASE4","title":"Concurrent Versus Sequential Administration of Tdap and RSV Vaccines in Pregnancy","status":"RECRUITING","sponsor":"Canadian Immunization Research Network","startDate":"2025-10-16","conditions":"RSV, Tdap - Tetanus, Diphtheria and Acellular Pertussis Vaccination, Pregnancy","enrollment":60},{"nctId":"NCT05269381","phase":"PHASE1, PHASE2","title":"Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2022-03-31","conditions":"Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8","enrollment":132},{"nctId":"NCT07078604","phase":"PHASE2","title":"A Cancer Vaccine (STEMVAC) in Combination With Chemotherapy for the Treatment of PD-L1 Negative Metastatic Triple-Negative Breast Cancer","status":"RECRUITING","sponsor":"University of Washington","startDate":"2026-04-11","conditions":"Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma","enrollment":20},{"nctId":"NCT02410733","phase":"PHASE1","title":"Evaluation of the Safety and Tolerability of i.v. Administration of a Cancer Vaccine in Patients With Advanced Melanoma","status":"COMPLETED","sponsor":"BioNTech SE","startDate":"2015-03","conditions":"Melanoma","enrollment":119},{"nctId":"NCT05098210","phase":"PHASE1","title":"Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer","status":"RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2022-06-09","conditions":"Anatomic Stage IV Breast Cancer AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Locally Advanced Cutaneous Melanoma","enrollment":25},{"nctId":"NCT03172975","phase":"PHASE2","title":"Efficacy of Na-GST-1/Alhydrogel Hookworm Vaccine Assessed by Controlled Challenge Infection","status":"COMPLETED","sponsor":"Baylor College of Medicine","startDate":"2018-03-01","conditions":"Hookworm Infections","enrollment":39},{"nctId":"NCT06011772","phase":"EARLY_PHASE1","title":"EGF-Depleting Therapy CIMAvax-EGF in Combination With Standard Therapy for RAS- and BRAF Wild-Type Metastatic Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Roswell Park Cancer Institute","startDate":"2023-12-18","conditions":"Colo-rectal Cancer","enrollment":2},{"nctId":"NCT06202066","phase":"PHASE2","title":"Temozolomide and Survivin Long Peptide Vaccine (SurVaxM) for the Treatment of Patients With Progressing Metastatic Neuroendocrine Carcinomas","status":"RECRUITING","sponsor":"Roswell Park Cancer Institute","startDate":"2026-04-15","conditions":"Digestive System Neuroendocrine Neoplasm, Lung Neuroendocrine Neoplasm, Malignant Solid Neoplasm","enrollment":60},{"nctId":"NCT05142553","phase":"PHASE2","title":"Immunogenicity and Safety of a Booster Vaccination With a Recombinant Protein RBD Candidate Vaccine Against SARS-CoV-2 in Healthy Adults Volunteers Fully Vaccinated Followed by an Extension Period to Study a Fourth Dose Administration.","status":"COMPLETED","sponsor":"Hipra Scientific, S.L.U","startDate":"2021-11-16","conditions":"COVID-19, SARS-CoV-2 Acute Respiratory Disease","enrollment":887},{"nctId":"NCT05743595","phase":"PHASE1","title":"Neoantigen-based Personalized DNA Vaccine With Retifanlimab PD-1 Blockade Therapy in Patients With Newly Diagnosed, Unmethylated Glioblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2023-10-27","conditions":"Unmethylated Glioblastoma","enrollment":27},{"nctId":"NCT06229392","phase":"PHASE1","title":"A Study to Evaluate the Intratumoral Influenza Vaccine Administration in Patients With Breast Cancer","status":"WITHDRAWN","sponsor":"Rush University Medical Center","startDate":"2026-06-01","conditions":"Breast Cancer, Breast Cancer Triple Negative","enrollment":0},{"nctId":"NCT03036930","phase":"PHASE2","title":"Preventive Human Papillomavirus (HPV) Vaccine Trial in Kidney Transplant Recipients","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2017-06-23","conditions":"Human Papillomavirus Infection, Human Papillomavirus-Related Carcinoma","enrollment":51},{"nctId":"NCT07460154","phase":"NA","title":"Structured Review: To Optimise Management and Prevent Harm in COPD","status":"NOT_YET_RECRUITING","sponsor":"Northumbria Healthcare NHS Foundation Trust","startDate":"2026-03-01","conditions":"COPD","enrollment":96},{"nctId":"NCT06059391","phase":"PHASE2","title":"CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2024-07-12","conditions":"Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia","enrollment":216},{"nctId":"NCT06599658","phase":"PHASE2","title":"COVID-19 Booster and IIV Schedule in Immunocompromised Hosts","status":"RECRUITING","sponsor":"McGill University Health Centre/Research Institute of the McGill University Health Centre","startDate":"2024-11-20","conditions":"COVID 19, Influenza, Rheumatoid Arthritis (RA)","enrollment":660},{"nctId":"NCT04697576","phase":"PHASE1","title":"Intralesional Influenza Vaccine for the Treatment of Stage I-IV Melanoma","status":"RECRUITING","sponsor":"Carlo Contreras","startDate":"2021-10-20","conditions":"Clinical Stage I Cutaneous Melanoma AJCC v8, Clinical Stage IA Cutaneous Melanoma AJCC v8, Clinical Stage IB Cutaneous Melanoma AJCC v8","enrollment":36},{"nctId":"NCT07459946","phase":"NA","title":"Research on Innovative Traditional Chinese Medicine Diagnosis and Treatment Technologies for Diabetic Nephropathy Driven by Multi-Omics and Artificial Intelligence","status":"NOT_YET_RECRUITING","sponsor":"Jiazhen Yin","startDate":"2026-03-12","conditions":"Diabetic Nephropathy Type 2, Chronic Renal Failure/ Kidney Disease","enrollment":198},{"nctId":"NCT06098690","phase":"NA","title":"Culturally Tailored HPV Psychoeducational Multimedia Intervention","status":"RECRUITING","sponsor":"University of Texas, El Paso","startDate":"2024-05-02","conditions":"Health Knowledge, Attitudes, Practice, Vaccine-Preventable Diseases, Intention","enrollment":63},{"nctId":"NCT06253533","phase":"PHASE1","title":"ICVAX as a HIV Therapeutic DNA Vaccine","status":"COMPLETED","sponsor":"Immuno Cure Holding (HK) Limited","startDate":"2023-02-14","conditions":"Human Immunodeficiency Virus, Human Immunodeficiency Virus I Infection","enrollment":45},{"nctId":"NCT06050356","phase":"PHASE1","title":"First-in-Human Trial of the Novel Tuberculosis Vaccine Candidate, H107e/CAF®10b","status":"ACTIVE_NOT_RECRUITING","sponsor":"Statens Serum Institut","startDate":"2024-03-14","conditions":"Healthy","enrollment":140},{"nctId":"NCT06251024","phase":"PHASE2","title":"Study of a Respiratory Syncytial Virus Candidate Formulation in Adults Aged 60 Years and Older","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2024-04-02","conditions":"Respiratory Syncytial Virus Infection, Healthy Volunteers","enrollment":4541},{"nctId":"NCT05660408","phase":"PHASE1, PHASE2","title":"RNA Lipid Particles Targeting Pediatric Recurrent Intracranial Malignancies and Other systEmic Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Florida","startDate":"2025-03-12","conditions":"Recurrent Pulmonary Osteosarcoma, Recurrent High-grade Glioma","enrollment":36},{"nctId":"NCT02858310","phase":"PHASE1, PHASE2","title":"E7 TCR T Cells for Human Papillomavirus-Associated Cancers","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2017-01-27","conditions":"Papillomavirus Infections, Cervical Intraepithelial Neoplasia, Carcinoma In Situ","enrollment":224},{"nctId":"NCT07112053","phase":"PHASE2","title":"A Vaccine (STEMVAC) With Standard Endocrine-Based Therapy or Chemotherapy for the Treatment of Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer","status":"RECRUITING","sponsor":"University of Washington","startDate":"2025-11-17","conditions":"Anatomic Stage IV Breast Cancer AJCC v8, Metastatic HER2-Negative Breast Carcinoma, Metastatic Hormone Receptor-Positive Breast Carcinoma","enrollment":40},{"nctId":"NCT06254326","phase":"PHASE1","title":"ADAGiO: Adoptive Cellular Therapy for the TreAtment of Recurrent OliGodendrogliOma (OG) Adult Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Florida","startDate":"2024-09-19","conditions":"Recurrent Oligodendroglioma, Progressive Oligodendroglioma","enrollment":12},{"nctId":"NCT07217145","phase":"NA","title":"PREVENT HPV -Related Cancers Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Utah","startDate":"2025-10-09","conditions":"HPV Vaccination, Uptake Vaccination, Series Completion","enrollment":1455},{"nctId":"NCT06049134","phase":"PHASE4","title":"Immunogenicity and Clinical Efficacy of 20-valent Pneumococcal Conjugate Vaccine (PCV20) in Lymphoma Survivors After Treatment With Anti-CD20 Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2023-10-06","conditions":"Lymphoma","enrollment":30},{"nctId":"NCT07454915","phase":"PHASE2","title":"PVX4 for the Treatment of Human Papilloma Virus (HPV)16+ Cervical Dysplasia","status":"NOT_YET_RECRUITING","sponsor":"PapiVax Biotech, Inc.","startDate":"2026-03-01","conditions":"Cervical Intraepithelial Neoplasia Grade 2/3, Human Papilloma Virus Infection Type 16","enrollment":138},{"nctId":"NCT07455318","phase":"PHASE3","title":"Boostability Assessment of Three Rabies Pre-Exposure Regimens in Healthy Volunteers 5 Years Following Priming.","status":"NOT_YET_RECRUITING","sponsor":"Institute of Tropical Medicine, Belgium","startDate":"2026-05-15","conditions":"Rabies (Healthy Volunteers)","enrollment":561},{"nctId":"NCT06973772","phase":"PHASE3","title":"Trial to Evaluate the Immunogenicity and Safety of the Co-administration of Live Attenuated Dengue and Chikungunya Vaccines Compared to Separate Administration in Adults Aged 18 to 59 Years.","status":"NOT_YET_RECRUITING","sponsor":"Butantan Institute","startDate":"2026-03-31","conditions":"Dengue, Chikungunya","enrollment":900},{"nctId":"NCT03384914","phase":"PHASE2","title":"Vaccine to Prevent Recurrence in Patients With HER-2 Positive Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2018-02-19","conditions":"Breast Cancer Female, Breast Cancer, Male, Breast Cancer Stage I","enrollment":119},{"nctId":"NCT05801913","phase":"PHASE1","title":"Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) for the Treatment of Intermediate or High Grade B-Cell Non-Hodgkin Lymphoma","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2023-09-29","conditions":"High Grade B-Cell Non-Hodgkin's Lymphoma, Intermediate Grade B-Cell Non-Hodgkin's Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma","enrollment":15},{"nctId":"NCT06485258","phase":"PHASE1","title":"CDC-9 Inactivated Rotavirus Vaccine (IRV) Intramuscular (IM) Phase 1 Clinical Trial in Healthy Adults","status":"COMPLETED","sponsor":"Centers for Disease Control and Prevention","startDate":"2024-08-06","conditions":"Rotavirus Infections","enrollment":50},{"nctId":"NCT06962904","phase":"PHASE1","title":"CDC-9 Inactivated Rotavirus Vaccine (IRV) Microneedle Patch (MNP) in Healthy Adults","status":"ACTIVE_NOT_RECRUITING","sponsor":"Centers for Disease Control and Prevention","startDate":"2025-07-07","conditions":"Rotavirus Infections","enrollment":50},{"nctId":"NCT04144023","phase":"PHASE1","title":"A Vaccine (H2NVAC) Before Surgery for the Treatment of HER2-Expressing Ductal Carcinoma In Situ","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2019-06-27","conditions":"Breast Ductal Carcinoma In Situ","enrollment":43},{"nctId":"NCT04335890","phase":"PHASE1","title":"IKKb-matured, RNA-loaded Dendritic Cells for Metastasised Uveal Melanoma","status":"COMPLETED","sponsor":"Hasumi International Research Foundation","startDate":"2020-09-24","conditions":"Melanoma, Uveal Metastatic","enrollment":17},{"nctId":"NCT06868433","phase":"PHASE1","title":"TMV Vaccine Therapy Alone and With Pembrolizumab for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer","status":"RECRUITING","sponsor":"Emory University","startDate":"2025-05-08","conditions":"Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Hypopharyngeal Squamous Cell Carcinoma","enrollment":40},{"nctId":"NCT06680479","phase":"PHASE1","title":"Safety and Immunogenicity of Stabilized CH505 TF chTrimer Vaccination in Adults Living With HIV-1 on Suppressive Antiretroviral Therapy","status":"SUSPENDED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2025-04-01","conditions":"HIV-1","enrollment":30},{"nctId":"NCT05078866","phase":"PHASE1, PHASE2","title":"Cancer Preventive Vaccine Nous-209 for Lynch Syndrome Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-11-10","conditions":"Colorectal Carcinoma, Lynch Syndrome","enrollment":45},{"nctId":"NCT07445815","phase":"PHASE2","title":"A Phase II Trial of a Recombinant Human Anti-Rabies Virus Monoclonal Antibody","status":"NOT_YET_RECRUITING","sponsor":"Lanzhou Institute of Biological Products Co., Ltd","startDate":"2026-01-31","conditions":"Rabies (Healthy Volunteers)","enrollment":200},{"nctId":"NCT00867464","phase":"","title":"Extended Follow Up of Young Women in Costa Rica Who Received Vaccine for Human Papillomavirus Types 16 and 18 and Unvaccinated Controls","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2009-03-30","conditions":"Anal Carcinoma, Cervical Carcinoma, Human Papillomavirus Infection","enrollment":8670},{"nctId":"NCT03855995","phase":"","title":"A Study Assessing the Safety, Efficacy, and Impact of GlaxoSmithKline Biologicals' RTS, S/AS01E Malaria Vaccine in Young Children Across Sub-Saharan Africa","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2019-03-21","conditions":"Malaria, Malaria Vaccines","enrollment":77953},{"nctId":"NCT05538663","phase":"PHASE3","title":"Intravesical BCG vs GEMDOCE in NMIBC","status":"ACTIVE_NOT_RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2023-02-07","conditions":"Non-muscle-invasive Bladder Cancer","enrollment":870},{"nctId":"NCT07443709","phase":"PHASE2","title":"Zoster Vaccine to Enhance Protection Against Zoster in Solid-organ Transplantation","status":"NOT_YET_RECRUITING","sponsor":"Oriol Manuel","startDate":"2026-04","conditions":"Zoster; Herpes","enrollment":75},{"nctId":"NCT05294588","phase":"PHASE2","title":"Efficacy of Immunization With 4C-MenB in Preventing Experimental Urethral Infection With Neisseria Gonorrhoeae","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2022-04-18","conditions":"Gonorrhea Male","enrollment":65},{"nctId":"NCT04915768","phase":"PHASE1","title":"Evaluating the Safety and Immunogenicity of Stabilized CH505 TF chTrimer in Healthy, HIV-uninfected Adult Participants.","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2023-01-23","conditions":"HIV Infections","enrollment":51},{"nctId":"NCT04006457","phase":"PHASE3","title":"Long-Term PF-06651600 for the Treatment of Alopecia Areata","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2019-07-18","conditions":"Alopecia Areata","enrollment":1052},{"nctId":"NCT05239403","phase":"","title":"Association Between Gut Microbiome and Dietary Determinants and Vaccine Response","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2021-08-24","conditions":"Influenza","enrollment":74},{"nctId":"NCT02455557","phase":"PHASE2","title":"SurVaxM Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Roswell Park Cancer Institute","startDate":"2015-05-04","conditions":"Glioblastoma, Gliosarcoma","enrollment":66},{"nctId":"NCT07348692","phase":"PHASE3","title":"Lot-to-lot Consistency Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From 2 Months of Age","status":"RECRUITING","sponsor":"Sanofi","startDate":"2026-01-20","conditions":"Pneumococcal Immunization, Healthy Volunteers","enrollment":896},{"nctId":"NCT03942328","phase":"PHASE1, PHASE2","title":"Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) Combined With Immune Checkpoint Inhibition After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2019-09-19","conditions":"Stage III Hepatocellular Carcinoma AJCC v8, Stage III Intrahepatic Cholangiocarcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8","enrollment":85},{"nctId":"NCT07430202","phase":"PHASE1","title":"A DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Glutamine Antagonist DRP-104, Nivolumab, and Ipilimumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC)","status":"NOT_YET_RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2026-05","conditions":"Liver Cancer (Fibrolamellar Hepatocellular Cancer (FLC))","enrollment":27}],"_emaApprovals":[{"date":"","name":"Vaccine administration","status":"Authorised","regulator":"EMA"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[{"role":"Manufacturer","site":"Natural Creations, Inc","location":"","operator":"Natural Creations, Inc"}],"molecularData":{"oral":false,"chemblId":"CHEMBL2108573","moleculeType":"Vaccine component","molecularWeight":""},"administration":{"route":"Oral"},"_patentsChecked":true,"_warningLetters":[{"date":"03/27/2026","subject":"Feedback form"}],"crossReferences":{"chemblId":"CHEMBL2108573"},"formularyStatus":[],"_offLabelChecked":true,"developmentCodes":[],"ownershipHistory":[{"period":"?-present","_source":"FDA label","companyName":"Natural Creations, Inc","relationship":"Originator"}],"publicationCount":3182,"therapeuticAreas":["Immunology"],"biosimilarFilings":[],"recentPublications":[{"date":"2026 Mar 6","pmid":"41893778","title":"Safety of Sabin-Strain Inactivated Poliovirus Vaccine Administered Alone or Concomitantly with Other Vaccines: A Population-Based Post-Marketing Surveillance Study.","journal":"Vaccines"},{"date":"2026 Feb","pmid":"41869104","title":"Complementary Vaccination in Morocco's Pediatric Population: A Cross-Sectional Study at Mohamed VI University Hospital, Oujda.","journal":"Cureus"},{"date":"2026 Mar 17","pmid":"41845916","title":"Safety of Live and Live-Attenuated Vaccines in Patients Receiving Biologics and Small-Molecule Therapies for Dermatologic Diseases: A Systematic Review.","journal":"The Australasian journal of dermatology"},{"date":"2026 Mar 1","pmid":"41840407","title":"Vaccinating patients on biologics for atopic disease: Clinical considerations and evidence-based recommendations.","journal":"Allergy and asthma proceedings"},{"date":"2026 Mar 16","pmid":"41839823","title":"Factors Impacting Intention of Dental Hygienists to Administer Vaccines in Dental Settings.","journal":"International journal of dental hygiene"}],"_drugWebsiteChecked":true,"_healthCanadaChecked":true,"companionDiagnostics":[],"_genericFilersChecked":true,"genericManufacturerList":[],"phase":"marketed","status":"active","companyName":"Women and Infants Hospital of Rhode Island","companyId":"women-and-infants-hospital-of-rhode-island","modality":"Biologic","firstApprovalDate":"","enrichmentLevel":3,"visitCount":8,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"EU","regulator":"EMA","status":"pending","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"GB","regulator":"MHRA","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"pricingByCountry":[{"country_code":"US","currency":"USD","price_amount":"80000.00","price_per":"year","price_type":"annual_list","annual_cost_usd":null,"reimbursement_status":null}],"trialStats":{"total":16,"withResults":7},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-19T23:31:15.309060+00:00","fieldsConflicting":2,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}